Parkinson's Disease Clinical Trial
Official title:
Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators
This clinical trial has been designed to study and compare changes in deep brain activity
(field potentials) in Parkinson's disease (PD) patients while awake, and during sedation
with dexmedetomidine or propofol. The recording is made through a deep brain stimulation
(DBS) electrode implanted for PD management.
The investigators hypothesize that dexmedetomidine produces fewer changes as compared to
propofol, and that those changes are consistent and recognizable when compared to activity
in patients not exposed to any sedation. Typification of those changes would in the future
allow for patients to undergo this surgery comfortably while not compromising the quality of
the recording and of the final clinical outcome. The principal variable analyzed is the
signal's power in each of the frequency bands, absolute and relative. The analysis will
include usual clinical methods such as rapid Fourier transform (FFT) and window fast Fourier
transform (WFFT), wavelet analysis, Gabor, and coherence.
Comparative clinical trial, non blinded, controlled and sequential, evaluating the effects
of propofol and dexmedetomidine in the basal ganglia of PD patients through a DBS electrode.
It is a phase IV clinical trial evaluating the effects of a drug outside the approved.
The study takes part in three phases:
1. DBS placement under sedation with dexmedetomidine at 0.2 μg/kg/h. This will be called
"dexmedetomidine record".
2. Four days later and with no sedation, a recording will be registered in one of the
specialized electrically isolated rooms at the Neurophysiology Department. This will be
dubbed "basal recording". The equipment used is also the standard one used for routine
postoperative recordings.
3. 5 days after the initial surgery, and following the protocol in place for these
procedures, the tunnelization and battery placement will take place. This is done under
general anaesthesia. During anaesthetic induction, the patient is exposed to
incremental doses of propofol. Different plasmatic concentrations will be targeted
using the mathematical model in the target controlled infusion (TCI) pump. These
recordings will be called "propofol at a 0.5, 1, 1.5, 2, 2.5 μg/mL".
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02939391 -
A Study of KW-6356 in Subjects With Early Parkinson's Disease
|
Phase 2 | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 |